| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 07.02.
| Oncothyreon Announces Presentations at Upcoming Investment Conferences in February 2012 | | 17 | PR Newswire |
| SEATTLE, WA, Feb. 7, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief
Executive Officer, will be presenting at the following upcoming
...
Mehr lesen zu:
Oncothyreon Announces Presentations at Upcoming Investment Conferences in February 2012 | |
| 01.02.
| Buyers Accumulate Shares of Oncothyreon, Up 9.1% | | 7 | SmarTrend |
| 09.01.
| Human Genome Sciences and Oncothyreon -- Strong Growth Stories for 2012 / Five Star Equities Provides Stock Research on Human Genome Sciences & Oncothyreon | | 66 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/09/12 -- Biotechnology stocks have performed well in the early stages of the New Year. Last Thursday, the NYSE Arca Biotechnology Index skyrocketed as much as 3...
Mehr lesen zu:
Human Genome Sciences and Oncothyreon -- Strong Growth Stories for 2012 / Five Star Equities Provides Stock Research on Human Genome Sciences & Oncothyreon | |
| 05.01.
| Oncothyreon Announces Promotion of Diana Hausman, M.D., to Chief Medical Officer | | 43 | PR Newswire |
| SEATTLE, WA, Jan. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced the promotion of Diana Hausman, M.D., to Chief Medical
Officer. Dr. Hausman joined Oncothyreon in August...
Mehr lesen zu:
Oncothyreon Announces Promotion of Diana Hausman, M.D., to Chief Medical Officer | |
| 20.12.
| Oncothyreon (ONTY) Files IND w/ FDA for ONT-10 | | 10 | StreetInsider.com |
| 20.12.
| Oncothyreon Files Investigational New Drug Application for ONT-10 | | 17 | PR Newswire |
| SEATTLE, WA, Dec. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the filing of an
Investigational New Drug (IND) application with the U.S. Food and Drug
Administration...
Mehr lesen zu:
Oncothyreon Files Investigational New Drug Application for ONT-10 | |
| 15.12.
| Notable Put Options Activity in Oncothyreon | | 8 | Benzinga.com |
| 08.12.
| Oncothyreon and Cyclacel Pharmaceuticals -- Strong Examples of Recession Proof Growth / The Paragon Report Provides Equity Research on Oncothyreon & Cyclacel Pharmaceuticals | | 30 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 12/08/11 -- The Biotechnology industry has long been regarded as a "Recession Proof" sector of the economy. Even during periods of financial turmoil, most people will...
Mehr lesen zu:
Oncothyreon and Cyclacel Pharmaceuticals -- Strong Examples of Recession Proof Growth / The Paragon Report Provides Equity Research on Oncothyreon & Cyclacel Pharmaceuticals | |
| 07.12.
| Oncothyreon to Present at Oppenheimer Healthcare Conference | | 9 | PR Newswire |
| SEATTLE, WA, Dec. 7, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief
Executive Officer, will be presenting at the Oppenheimer...
Mehr lesen zu:
Oncothyreon to Present at Oppenheimer Healthcare Conference | |
| 18.11.
| Zalicus and Oncothyreon -- Low Valuations Reawaken Investor Enthusiasm / The Bedford Report Provides Equity Research on Zalicus & Oncothyreon | | 28 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 11/18/11 -- Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper...
Mehr lesen zu:
Zalicus and Oncothyreon -- Low Valuations Reawaken Investor Enthusiasm / The Bedford Report Provides Equity Research on Zalicus & Oncothyreon | |
| 14.11.
| Oncothyreon (ONTY) Reports Data for Two PX-866 Phase 1/2s | | 5 | StreetInsider.com |
| 13.11.
| Oncothyreon Presents Data from Phase 1/2 Trials of PX-866 in Combination with Docetaxel and with Cetuximab at 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | | 105 | PR Newswire |
| SEATTLE, Nov. 13, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced the presentation of data from two Phase 1/2 trials of PX-866,
an irreversible, pan-isoform phosphatidylinositol-3-kinase...
Mehr lesen zu:
Oncothyreon Presents Data from Phase 1/2 Trials of PX-866 in Combination with Docetaxel and with Cetuximab at 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | |
| 08.11.
| Oncothyreon Reports Third Quarter 2011 Financial Results | | 18 | PR Newswire |
| Company to Hold Conference Call at 4:30 p.m. EST Today
SEATTLE, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
reported financial results for the third quarter ending September...
Mehr lesen zu:
Oncothyreon Reports Third Quarter 2011 Financial Results | |
| 08.11.
| Oncothyreon to Present at Lazard Capital Markets Healthcare Conference | | 7 | PR Newswire |
| SEATTLE, WA, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that the company will be presenting at the Lazard
Capital Markets 8th Annual Healthcare Conference in New...
Mehr lesen zu:
Oncothyreon to Present at Lazard Capital Markets Healthcare Conference | |
| 01.11.
| Oncothyreon Announces Third Quarter 2011 Financial Results Conference Call | | 9 | PR Newswire |
| SEATTLE, WA, Nov. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced that it will conduct a conference call to discuss its third
quarter 2011 financial results and provide a...
Mehr lesen zu:
Oncothyreon Announces Third Quarter 2011 Financial Results Conference Call | |
| 21.10.
| Cardium Therapeutics and Oncothyreon Poised for Growth / The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon | | 48 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 10/21/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly...
Mehr lesen zu:
Cardium Therapeutics and Oncothyreon Poised for Growth / The Paragon Report Provides Equity Research on Cardium Therapeutics & Oncothyreon | |
| 20.10.
| Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Docetaxel | | 4 | PR Newswire |
| SEATTLE, WA, Oct. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced it has initiated the Phase 2 portion of its ongoing Phase
1/2 trial of PX-866 in combination with the...
Mehr lesen zu:
Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Docetaxel | |
| 17.10.
| Oncothyreon to Present at BioCentury NewsMakers in the Biotech Industry Conference | | 11 | PR Newswire |
| SEATTLE, WA, Oct. 17, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY)
announced today that the company will be presenting at the BioCentury
NewsMakers in the Biotech Industry Conference in...
Mehr lesen zu:
Oncothyreon to Present at BioCentury NewsMakers in the Biotech Industry Conference | |
| 12.09.
| Oncothyreon (ONTY) Enrolls First Patient in PX-866 Phase 2 | | 5 | StreetInsider.com |
| 12.09.
| Oncothyreon (ONTY), Sanford-Burnham Enter Sabutoclax Licensing Agreement | | 2 | StreetInsider.com |
